Diabetes Research Team is focused at understanding the
causes of type 2 diabetes and investigating therapies
to mitigate and ultimately cure the disease. Key to this
mission is collaborative research between scientists who
work in the laboratory and physicians who work directly
with patients. We initiated this "bench-to-bedside" model
means that scientific findings in the laboratory can be
translated into medical treatments with the potential
to benefit those who live with diabetes. Our efforts are
to learn how to prevent type 2 diabetes by gaining a clear
understanding of the hot targets responsible for onset
and occurrence of type 2 diabetes mellitus. We also seek
to test safe, innovative new therapies that might slow
the onset of type 2 diabetes.
 |
Exploration of natural resources/synthetic
products to develop the newer anti-diabetics. |
|
Develop the safe and efficacious remedy
for type 2 diabetes. |
|
Promote the training of scientists
in developing new understandings of the basis of
the type 2 diabetes mellitus and its complications.
|
|
Blood glucose and lipid profiling |
|
In vitro and in vivo
insulin estimation |
|
Hb1Ac estimation |
| Sr. NO |
Name |
Expertise |
E-mail |
| 1. |
Zabeer Ahmed |
In Vitro & In Vivo studies of type
2 diabetes |
zahmed@iiim.res.in |
| 2. |
Asha Bhagat |
Screening of natural molecules for
anti-diabetic activity |
abhagat@iiim.res.in |
|
Pre-clinical development of herbal
based extracts and molecules of synthetic origin
for Diabetes Mellitus type 2 with focus on insulin
sensitization. |
|
Focused to deliver safe and efficacious
remedy for Non-insulin dependent diabetes mellitus
(NIDDM) with property to normalize the total metabolic
state particularly the lipids. |
|
Spectrophotometer cum Plate reader
|
|
Cell culture facility |
|
Micro-plate shaker |
|
Shaker Water bath |
|
pH meter |
|
Inverted Microscope |
Anti-diabetic activity
|
Hypoglycemic activity |
|
Antihyperglycemic activity |
|
Insulin secretion |
Pre-clinical development of herbal extracts and formulations
|
Acute toxicity |
|
Sub-acute toxicity |
|
Sub-chronic toxicity |
MLP-1006: Newer Antidiabetic formulation(s) of natural
and synthetic origin.
April, 2009 to March, 2010
|
